ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will ...
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potentialNEW YORK, ...
RNA modifications have emerged as a crucial area of research within molecular viral pathogenesis, providing new insights into how viruses hijack host gene ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...
People living with HIV represent a unique population in the field of infectious disease and immunology due to persistent immune dysregulation and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results